SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Coronavirus / COVID-19 Pandemic

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Glenn Petersen10/27/2020 6:57:04 AM
1 Recommendation

Recommended By
Moonray

   of 20291
 
Lilly antibody drug fails in a Covid-19 study; others go on

PUBLISHED MON, OCT 26 20208:02 PM EDT
UPDATED MON, OCT 26 20208:06 PM EDT
Associated Press via CNBC.com

KEY POINTS

-- Independent monitors had paused enrollment in the study two weeks ago because of a possible safety issue.

-- But on Monday, the National Institute of Allergy and Infectious Diseases, which sponsors the study, said a closer look did not verify a safety problem but found a low chance that the drug would prove helpful for hospitalized patients.

-- In a statement Lilly notes that the government is continuing a separate study testing the antibody drug in mild to moderately ill patients, to try to prevent hospitalization and severe illness.

U.S. government officials are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalized with Covid-19 because it doesn’t seem to be helping them.

Independent monitors had paused enrollment in the study two weeks ago because of a possible safety issue. But on Monday, the National Institute of Allergy and Infectious Diseases, which sponsors the study, said a closer look did not verify a safety problem but found a low chance that the drug would prove helpful for hospitalized patients.

It is a setback for one of the most promising treatment approaches for Covid-19. President Donald Trump received a similar experimental, two-antibody drug from Regeneron Pharmaceuticals Inc. on an emergency basis when he was sickened with the coronavirus earlier this month.

In a statement Lilly notes that the government is continuing a separate study testing the antibody drug in mild to moderately ill patients, to try to prevent hospitalization and severe illness. The company also is continuing its own studies testing the drug, which is being developed with the Canadian company AbCellera.

Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. The experimental drugs are concentrated versions of one or two specific antibodies that worked best against the coronavirus in lab and animal tests.

Lilly and Regeneron have asked the U.S. Food and Drug Administration to grant emergency use authorization for their drugs for Covid-19 while late-stage studies continue. Lilly says its request is based on other results suggesting the drug helps patients who are not hospitalized, and that it will continue to seek the FDA’s permission for emergency use.

cnbc.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext